50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:CKPT

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

$0.98
-0.08 (-7.53%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.97
$1.06
50-Day Range
$1.05
$1.47
52-Week Range
$0.96
$4.64
Volume
429,915 shs
Average Volume
835,763 shs
Market Capitalization
$90.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Checkpoint Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,925.4% Upside
$19.75 Price Target
Short Interest
Healthy
3.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.63
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.71) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

836th out of 1,069 stocks

Pharmaceutical Preparations Industry

399th out of 533 stocks

CKPT stock logo

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Stock News Headlines

Checkpoint: Strong Data, But Comes With Risks
Checkpoint Therapeutics GAAP EPS of -$0.20
Novato PD To Hold DUI Checkpoint
See More Headlines
Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Company Calendar

Last Earnings
8/12/2022
Today
9/26/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CKPT
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.75
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+1,273.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,670,000.00
Net Margins
-62,618.26%
Pretax Margin
-62,618.26%

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$0.34 per share

Miscellaneous

Free Float
87,780,000
Market Cap
$90.91 million
Optionable
Not Optionable
Beta
1.66

Key Executives

  • Mr. James F. Oliviero III (Age 46)
    C.F.A., CFA, Pres, CEO & Director
    Comp: $874.8k
  • Mr. William Garrett GrayMr. William Garrett Gray (Age 35)
    CFO, Corp. Sec. & Treasurer
    Comp: $350.94k













CKPT Stock - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings
or view top-rated stocks.

What is Checkpoint Therapeutics' stock price forecast for 2022?

2 Wall Street analysts have issued 12 month price targets for Checkpoint Therapeutics' shares. Their CKPT share price forecasts range from $7.00 to $26.00. On average, they anticipate the company's stock price to reach $19.75 in the next year. This suggests a possible upside of 1,763.2% from the stock's current price.
View analysts price targets for CKPT
or view top-rated stocks among Wall Street analysts.

How have CKPT shares performed in 2022?

Checkpoint Therapeutics' stock was trading at $3.11 at the beginning of 2022. Since then, CKPT shares have decreased by 65.9% and is now trading at $1.06.
View the best growth stocks for 2022 here
.

When is Checkpoint Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CKPT earnings forecast
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.07 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 273.30% and a negative net margin of 62,618.26%.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Jess S & Co. Inc. (1.25%), Millennium Management LLC (0.92%), Renaissance Technologies LLC (0.83%), Park Avenue Securities LLC (0.12%), Apollon Wealth Management LLC (0.11%) and Virtu Financial LLC (0.05%). Insiders that own company stock include James F Oliviero III, Lindsay A Md Rosenwald and William Garrett Gray.
View institutional ownership trends
.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $1.06.

How much money does Checkpoint Therapeutics make?

Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $98.05 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com.

This page (NASDAQ:CKPT) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.